Sakar Healthcare Q2 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹2,319 Cr
- P/E
- 54.11
- ROE
- 9.99%
- PEG
- 1.59
- Price to sales
- 7.68
- Debt to equity
- 0.13
- 52W high / low
- ₹1,188 / ₹362
- Sales growth (5Y)
- 21.55%
- EBITDA margin
- 29.96%
- Net profit margin
- 12.13%
- Promoter holding
- 51.70%
- Sales (last year)
- ₹302 Cr
Incorporated in 2004, Sakar Healthcare Ltd is in the business of manufacturing Research & Development of Pharmaceutical products[1]
Guidance scorecard · Q2 FY27 call
What Sakar Healthcare's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ2 FY27 call
20–40%- Oncology business is expected to grow at a rate of 35%+ revenue-wise in FY27 and FY28, maintaining strong momentum.
- Revenue target for oncology is INR300 crores in FY28, up from INR190-200 crores currently.
- Incremental growth to INR300 crores in FY28 will mainly come from site transfers and exports, with own marketing authorizations (MAs) contributing INR25-30 crores.
- Expansion in contract manufacturing from agreements like Accord is expected to scale up to around INR100 crores in 2 years.
- Oncology is projected to cross 50% of total revenue share next year, eventually reaching over 60% in 2-3 years.
- Growth driven by approvals and commercialization of 16 out of 22 MAs currently in pipeline and multiple site variations.
2 more points from Sakar Healthcare's call on revenue
Create a free account to keep reading this call
MarginsQ2 FY27 call
Up 2%+See what Sakar Healthcare said on margins — free account, 30 seconds.
CapexQ2 FY27 call
Planned- The company is focusing on integration of APIs in-house to improve margins over the next 2 years.
- They are procuring CEP (Certificates of Suitability) for around 20 key oncology API products to support backward integration.
- Emphasis on regulatory approvals, commercialization of oncology products, and scaling partnerships rather than direct capital investments.
FundraisingQ2 FY27 call
See what Sakar Healthcare said on fundraising — free account, 30 seconds.
Order bookQ2 FY27 call
Rising- Sakar Healthcare currently has 33 technology transfer projects underway with four partners, indicating a strong active pipeline.
- They have 11 products under tech transfer/site variation approved at their site, with expectations to scale these further.
- The Accord contract alone has the potential to generate around INR 100 crores as an average figure over the next couple of years.
- They have submitted approximately 191 dossiers across more than 40 countries, covering around 69 partnerships globally.
- Around 22 marketing authorizations (MAs) are in process, with expectations of partial approvals contributing revenue next year and more approvals by FY28.
2 more points from Sakar Healthcare's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Sakar Healthcare latest results (Sep 2026)
Revenue
₹87 Cr
+52% YoY
Net profit
₹11 Cr
+120% YoY
Operating margin
28%
EPS
₹5.08
Sakar Healthcare shareholding (Sep 2026)
Promoters
51.70%
−0.82 pp QoQ
FIIs
12.34%
+0.21 pp QoQ
DIIs
11.92%
+0.55 pp QoQ
Public
24.04%
+0.06 pp QoQ
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹3,041 Cr | 33.1 | |
| 2 | 40%+ | Up 2%+ | ₹492 Cr | 19.6 | |
| 3 | 40%+ | Up 0–2% | ₹234 Cr | 17.8 | |
| 4 | 40%+ | Flat | ₹18,347 Cr | — | |
| 5 | 40%+ | Flat | ₹8,432 Cr | 32.4 | |
| 6 | 40%+ | Flat | ₹4,295 Cr | — |
Sign up free to see every company in the sector ranking and track Sakar Healthcare.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Sakar Healthcare
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Sakar Healthcare
Shareholding breakup across reporting periods.
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters + | 53.15% | 53.15% | 53.15% | 53.15% | 53.58% | 53.58% | 52.86% | 52.86% | 52.86% | 52.86% | 52.52% | 51.70% |
| FIIs + | 13.76% | 13.52% | 13.52% | 13.42% | 13.58% | 13.61% | 13.41% | 13.31% | 13.05% | 12.94% | 12.13% | 12.34% |
| DIIs + | 10.62% | 10.62% | 10.62% | 10.62% | 10.88% | 10.97% | 11.25% | 11.43% | 11.36% | 11.32% | 11.37% | 11.92% |
| Public + | 22.47% | 22.71% | 22.71% | 22.80% | 21.96% | 21.85% | 22.48% | 22.41% | 22.73% | 22.87% | 23.98% | 24.04% |
| No. of Shareholders | 7,001 | 7,386 | 7,313 | 7,867 | 8,598 | 8,608 | 8,115 | 7,565 | 7,069 | 9,580 | 14,734 | 19,539 |
Financials of Sakar Healthcare
Quarterly Results
Quarter-by-quarter operating performance
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 34 | 37 | 43 | 41 | 43 | 43 | 50 | 53 | 58 | 70 | 71 | 73 | 87 |
| YoY Sales growth | +11% | +11% | +6% | +6% | +26% | +17% | +17% | +28% | +35% | +62% | +42% | +38% | +52% |
| Expenses + | 25 | 28 | 32 | 30 | 31 | 32 | 35 | 40 | 46 | 52 | 45 | 52 | 63 |
| Operating Profit | 9 | 9 | 11 | 11 | 12 | 12 | 16 | 13 | 11 | 19 | 26 | 21 | 24 |
| OPM % | 27% | 24% | 25% | 26% | 27% | 27% | 31% | 24% | 20% | 26% | 37% | 29% | 28% |
| Other Income + | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 0 |
| Interest | 2 | 2 | 2 | 1 | 2 | 1 | 4 | 2 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 7 | 7 |
| Profit before tax | 4 | 3 | 5 | 5 | 5 | 5 | 6 | 5 | 5 | 11 | 18 | 15 | 16 |
| Tax % | 13% | 31% | 35% | 49% | 6% | 17% | 8% | 13% | 15% | 6% | 39% | 29% | 29% |
| Net Profit + | 4 | 2 | 3 | 2 | 5 | 5 | 6 | 5 | 5 | 10 | 11 | 10 | 11 |
| EPS in Rs | 1.70 | 0.95 | 1.43 | 1.11 | 2.21 | 2.06 | 2.62 | 2.10 | 2.04 | 4.61 | 4.95 | 4.62 | 5.08 |
Financials of Sakar Healthcare
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 35 | 41 | 44 | 53 | 68 | 83 | 95 | 128 | 133 | 153 | 178 | 251 | 302 |
| Sales growth | +18% | +18% | +7% | +20% | +29% | +22% | +14% | +35% | +4% | +15% | +16% | +42% | +48% |
| Expenses + | 27 | 33 | 34 | 40 | 51 | 63 | 72 | 99 | 100 | 115 | 128 | 182 | 211 |
| Operating Profit | 8 | 8 | 10 | 13 | 17 | 20 | 23 | 29 | 33 | 38 | 50 | 69 | 90 |
| OPM % | 22% | 20% | 23% | 24% | 25% | 24% | 24% | 23% | 25% | 25% | 28% | 27% | 30% |
| Other Income + | 0 | 0 | 1 | 0 | 1 | 2 | 1 | 2 | 5 | 3 | 1 | 2 | 2 |
| Interest | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 6 | 8 | 9 | 8 | 8 |
| Depreciation | 2 | 3 | 3 | 4 | 6 | 7 | 8 | 10 | 15 | 18 | 21 | 24 | 25 |
| Profit before tax | 2 | 3 | 5 | 6 | 9 | 12 | 13 | 19 | 17 | 16 | 22 | 40 | 60 |
| Tax % | 24% | 22% | 30% | 38% | 28% | 21% | 19% | 20% | 24% | 27% | 19% | 23% | |
| Net Profit + | 2 | 2 | 3 | 4 | 7 | 10 | 11 | 15 | 13 | 12 | 18 | 30 | 43 |
| EPS in Rs | 2.30 | 2.78 | 3.08 | 3.12 | 4.47 | 6.43 | 6.84 | 8.90 | 6.70 | 5.37 | 7.97 | 13.70 | 19.26 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Sakar Healthcare
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 11 | 12 | 15 | 15 | 16 | 17 | 19 | 22 | 22 | 22 | 22 |
| Reserves | 7 | 11 | 25 | 39 | 57 | 66 | 83 | 110 | 154 | 241 | 264 | 302 | 324 |
| Borrowings + | 25 | 22 | 24 | 11 | 11 | 17 | 43 | 93 | 119 | 79 | 86 | 71 | 46 |
| Other Liabilities + | 11 | 10 | 11 | 18 | 15 | 17 | 37 | 47 | 44 | 47 | 43 | 86 | 124 |
| Total Liabilities | 50 | 51 | 71 | 81 | 97 | 115 | 178 | 268 | 336 | 389 | 415 | 481 | 516 |
| Fixed Assets + | 36 | 37 | 49 | 53 | 64 | 66 | 69 | 205 | 267 | 314 | 309 | 326 | 334 |
| CWIP | 0 | 0 | 0 | 0 | 9 | 13 | 49 | 1 | 6 | 0 | 17 | 4 | 6 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 3 | 0 | 0 | 0 | 0 |
| Other Assets + | 14 | 14 | 22 | 28 | 25 | 36 | 60 | 55 | 60 | 74 | 90 | 151 | 176 |
| Total Assets | 50 | 51 | 71 | 81 | 97 | 115 | 178 | 268 | 336 | 389 | 415 | 481 | 516 |
Financials of Sakar Healthcare
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 4 | 9 | 2 | 5 | 16 | 19 | 15 | 36 | 33 | 24 | 34 | 49 |
| Cash from Investing Activity + | -1 | -4 | -14 | -8 | -25 | -22 | -47 | -90 | -74 | -52 | -31 | -28 |
| Cash from Financing Activity + | -3 | -6 | 13 | -13 | 9 | 3 | 32 | 55 | 41 | 27 | -3 | -21 |
| Net Cash Flow | 1 | -1 | 0 | -16 | 0 | -0 | -0 | -0 | 0 | 0 | -0 | -0 |
| Free Cash Flow | 4 | 5 | -13 | -4 | -9 | -4 | -32 | -62 | -49 | -35 | 2 | 21 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 60% | 117% | 30% | 51% | 104% | 110% | 67% | 121% | 113% | 72% | 73% | 77% |
Financials of Sakar Healthcare
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 21 | 26 | 44 | 74 | 51 | 36 | 48 | 40 | 60 | 50 | 63 | 73 |
| Inventory Days | 142 | 107 | 114 | 51 | 70 | 92 | 112 | 69 | 76 | 121 | 193 | 207 |
| Days Payable | 20 | 66 | 51 | 57 | 41 | 46 | 141 | 149 | 129 | 120 | 93 | 153 |
| Cash Conversion Cycle | 143 | 67 | 107 | 68 | 80 | 83 | 19 | -39 | 7 | 51 | 163 | 127 |
| Working Capital Days | 27 | 10 | 67 | 98 | 31 | 31 | 2 | -11 | -6 | 29 | 52 | 45 |
| ROCE % | 14% | 14% | 15% | 14% | 16% | 16% | 13% | 12% | 9% | 7% | 9% | 12% |
Guidance history
How Sakar Healthcare's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q2 FY27 call → | 20–40% | Up 2%+ | Planned | — | Rising |
| Q1 FY27 call → | 40%+ | Up 2%+ | None planned | None planned | Rising |
| Q4 FY26 call → | 20–40% | Flat | Planned | — | Rising |
| Q3 FY26 call → | 40%+ | Up 2%+ | None planned | — | Rising |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
91 out of 100 — Strengthening
Over the past year its share price has done better than most of the stocks we track.
| Period | Share price change | Better than … of 1,937 stocks |
|---|---|---|
| Last 12 months | +160.0% | 97% |
| Last 6 months | +49.6% | 88% |
| Last 3 months | +19.0% | 86% |
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,937 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Sakar Healthcare: 0.4 × 97 + 0.4 × 88 + 0.2 × 86 = 91.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 13 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Sakar Healthcare: frequently asked questions
What is Sakar Healthcare share price today?
Sakar Healthcare last traded at ₹1,042.4, with a market capitalisation of ₹2,319 Cr and a P/E ratio of 54.1.
What were Sakar Healthcare's latest quarterly results?
For the quarter ended Sep 2026, Sakar Healthcare reported revenue of ₹87 Cr (+52% year on year) and net profit of ₹11 Cr, with an operating margin of 28%.
Is Sakar Healthcare's profit growing?
Net profit was ₹11 Cr in Sep 2026 against ₹5 Cr in Sep 2025, a change of +120%.
What is Sakar Healthcare's EPS?
Sakar Healthcare's earnings per share for the quarter ended Sep 2026 was ₹5.08.
What is the promoter holding in Sakar Healthcare?
Promoters held 51.70% of Sakar Healthcare in Sep 2026 (−0.82 pp versus Jun 2026).
How much do FIIs and DIIs hold in Sakar Healthcare?
In Sep 2026, foreign institutional investors held 12.34% and domestic institutions (including mutual funds) held 11.92% of Sakar Healthcare.
What is Sakar Healthcare's ROE and ROCE?
Sakar Healthcare's return on equity is 9.99% and its return on capital employed is 12.4%.
Does Sakar Healthcare pay a dividend?
Sakar Healthcare's dividend yield is 0% at the current price; see the Sakar Healthcare dividends page for past payouts.
Which sector does Sakar Healthcare belong to?
Sakar Healthcare is in the Pharmaceuticals & Biotechnology sector. Its peer comparison and sector ranking are on this page.
What did Sakar Healthcare's management say on the latest earnings call?
Arthneeti's analysis of the Q2 FY27 earnings call covers revenue, margins, capex and fundraising guidance from Sakar Healthcare's management.
How does Arthneeti AI analyse Sakar Healthcare?
Arthneeti reads Sakar Healthcare's earnings call transcripts and filings and scores revenue growth, margins, capex and fundraising, then ranks the company against its sector.
Continue your research
What Sakar Healthcare's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q2 FY27)
11.67% increase. Key results statement takeaways from Natural Capsules Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Sotac Pharmaceuticals (Q2 FY27)
7,654.95 lakhs; Operating margin ≈ 10.68% for HY Sep 2026 . Key results statement takeaways from Sotac Pharmaceuticals Ltd's Q2 FY27 results statement — and how
- Bio Medica Lab (Q2 FY27)
EBITDA for the quarter:** ₹510 lakhs, up 25% year-on-year (YoY). Key results statement takeaways from Bio Medica Laboratories Ltd's Q2 FY27 results statement —
- Syncom Formulations (India) (Q2 FY27)
Quarterly Revenue (Q2 FY 2026-27 ended 30/09/2026):** ₹14,821.08 lakhs (Unaudited) . Key results statement takeaways from Syncom Formulations (India) Ltd's Q2 F